Postprandial GlucoseNCT07918196
Postprandial Glycemic and GLP-1 Responses to Modified Full-sugar Drinks
A study testing Sucrose Beverage, Glucose + Fructose beverage and Sucrose with EGCG Beverage in people with Postprandial Glucose and GLP-1 Concentration, run by Purdue University at 1 site in United States.
Trial summary
This randomized, double-blind, crossover study will evaluate postprandial blood glucose and glucagon-like peptide-1 (GLP-1) responses to different sugar-containing beverages in healthy adults. Read more about this study
- Who is it for?
- Ages 18 to 45 yearsHealthy volunteers can take part
- Conditions the study is for
- Postprandial Glucose, GLP-1 Concentration, Satiety
- What is being tested?
- Sucrose Beverage, Glucose + Fructose beverage and Sucrose with EGCG Beverage
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 16 participants
- Where
- 1 siteUnited States
- Study dates
- 21 Oct 2026to Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Adults aged 18 to 45 years at the time of enrollment (self-report)
- Body mass index (BMI) between 18.5 and 24.9 kg/m² (self-report in prescreening questionnaire and confirmed in screening with height and weight measurements)
- Fasting blood glucose ≤100 mg/dL (assessed in the screening visit by finger prick)
- HbA1c ≤ 5.7% (assessed in the screening visit by finger prick)
- Non-smokers (self-report)
- Availability to provide written informed consent
Who cannot join
- Diabetic or pre-diabetic or use of glucose-lowering medications.
- Pregnant or lactating individuals.
- Use of medications or supplements known to affect glucose metabolism or gastrointestinal function. Examples: corticosteroids, beta-blockers, insulin, metformin, statins, vitamin C, vitamin E.
- History of gastrointestinal disease or surgery affecting digestion or absorption, such as irritable bowel syndrome, Crohn's disease, celiac disease, or major GI surgery.
- Known allergy or intolerance to study beverage components, including caffeine or EGCG.
- Current use of tobacco, vaping, or nicotine products.
Show all 9Show fewer
- Acute illness at the time of a study visit or inability to comply with study procedures (e.g., fasting, repeated sampling).
- Individuals with a history of liver disease, known abnormal liver function, or use of medications or supplements associated with clinically significant hepatoxicity.
- Heavy alcohol consumption, defined as 8 or more standard drinks per week for women or 15 or more standard drinks per week for men, based on the National Institute on Alcohol Abuse and Alcoholism (NIAAA) criteria. One standard drink (14 g of pure alcohol) is equivalent to 12 oz of regular beer (5% alcohol), 5 oz of wine (12% alcohol), or 1.5 oz of distilled spirits (40% alcohol). Weekly alcohol intake will be estimated by asking the number of drinking days per week and the typical number of drinks consumed per drinking day.
Trial locations and contacts
1 site in 1 country.
United States1 site
Purdue Clinical Research Center (CRC)
West Lafayette, Indiana, 47907
About this study
This randomized, double-blind, crossover study will evaluate postprandial blood glucose and glucagon-like peptide-1 (GLP-1) responses to different sugar-containing beverages in healthy adults. The study will also evaluate whether the addition of epigallocatechin gallate (EGCG), a compound found in green tea, modifies glucose and GLP-1 responses. Participants will complete four study visits and consume a different study beverage at each visit. Blood samples will be collected to measure glucose, GLP-1, and insulin, and participants will complete questionnaires assessing satiety and sensory perception.
Read the detailed description
This study will investigate postprandial blood glucose and glucagon-like peptide-1 (GLP-1) responses to different sugar-containing beverages in healthy adults. The study will also examine whether the addition of epigallocatechin gallate (EGCG), a compound found in green tea, modifies postprandial glucose and GLP-1 responses. Additional outcomes include insulin, satiety, and sensory perception of the beverages.
The study will use a randomized, double-blind, crossover design in which each participant will complete four study visits and receive each of the four beverage conditions in a randomized order. The test beverages will contain sucrose or glucose plus fructose and will be provided with or without 200 mg of EGCG, according to the assigned treatment condition. Study visits will be separated by a washout period of at least one week.
Participants will consume a standardized evening meal before each study visit and will fast overnight for approximately 12 hours. At each study visit, an intravenous catheter will be placed for repeated blood collection. A fasting blood sample will be collected before consumption of the assigned beverage, followed by serial blood samples during the postprandial period. Blood samples will be analyzed for glucose, GLP-1, and insulin.
Participants will also complete questionnaires to assess satiety and sensory characteristics of the test beverages.
- Conditions
- Postprandial Glucose, GLP-1 Concentration, Satiety
- Being tested
- Sucrose Beverage, Glucose + Fructose beverage, Sucrose with EGCG Beverage, Glucose-Fructose with EGCG Beverage
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Sucrose BeverageDietary supplement
Carbonated test beverage containing sucrose as the carbohydrate source. Participants will consume the beverage during one study visit.
Glucose + Fructose beverageDietary supplement
Carbonated test beverage containing separate glucose and fructose as the carbohydrate sources. Participants will consume the beverage during one study visit.
Sucrose with EGCG BeverageDietary supplement
Carbonated test beverage containing sucrose as the carbohydrate source plus EGCG. Participants will consume the beverage during one study visit.
Glucose-Fructose with EGCG BeverageDietary supplement
Carbonated test beverage containing fructose and glucose as the carbohydrate source, plus EGCG. Participants will consume the beverage during one study visit.
| Study group | Role | What they receive |
|---|---|---|
| Sucrose beverage | Experimental | Participants will consume a sugar-containing carbonated beverage formulated with sucrose. Receives: Dietary Supplement: Sucrose Beverage |
| Sucrose + EGCG beverage | Experimental | Participants will consume a sugar-containing carbonated beverage formulated with sucrose and 200 mg EGCG. Receives: Dietary Supplement: Sucrose with EGCG Beverage |
| Glucose + Fructose beverage | Experimental | Participants will consume a sugar-containing carbonated beverage formulated with separate glucose and fructose. Receives: Dietary Supplement: Glucose + Fructose beverage |
| Glucose + Fructose +EGCG beverage | Experimental | Participants will consume a sugar-containing carbonated beverage formulated with separate glucose and fructose and 200 mg EGCG. Receives: Dietary Supplement: Glucose-Fructose with EGCG Beverage |
What is being measured
The primary outcome is the main question the study is designed to answer.
Postprandial blood glucose
Changes in plasma glucose concentrations following consumption of each test beverage.
Measured: Baseline (0 minutes) and 15, 30, 60, 90, 120, and 180 minutes after beverage consumption.
Postprandial GLP-1 response
Changes in plasma total glucagon-like peptide-1 (GLP-1) concentrations following consumption of each test beverage.
Measured: Baseline (0 minutes) and 15, 30, 60, 90, 120, and 180 minutes after beverage consumption.
Secondary outcomes (3)
Postprandial insulin response
Changes in plasma insulin concentrations following consumption of each test beverage.
Measured: Baseline (0 minutes) and 15, 30, 60, 90, 120, and 180 minutes after beverage consumption.
Satiety
Satiety and appetite will be assessed using a participant-reported questionnaire consisting of eight items measuring satisfaction, prospective food consumption, hunger, fullness, and desire to consume fatty, salty, sweet, or tasty foods. Each item is rated on an 11-point numerical rating scale ranging from 0 to 10. Higher scores indicate greater satisfaction, fullness, hunger, prospective food consumption, or desire to consume specific foods, depending on the item. Each item will be evaluated separately.
Measured: Baseline (0 minutes) and 15, 30, 45, 60, 90, 120, 150, and 180 minutes after beverage consumption.
Sensory perception of test beverages
Sensory perception will be assessed using participant-reported Visual Analog Scales (VAS) ranging from 0 to 100. Participants will evaluate sweetness intensity, bitterness intensity, astringency, and overall liking of each test beverage. For sweetness, bitterness, and astringency, 0 indicates no perceived intensity and 100 indicates the strongest intensity ever experienced. For overall liking, 0 indicates the worst experience and 100 indicates the best experience. Higher scores indicate greater perceived intensity or greater overall liking, respectively. Each attribute will be analyzed separately.
Measured: Immediately after beverage consumption during each study visit
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Nov 2026
- Study start21 Oct 2026
- Primary completionDec 2026 (estimated)
- Study completionDec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Postprandial GlucoseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 16 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Purdue University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Bruce R. Hamaker, Purdue University
- Investigators
- Bruce Hamaker, Principal investigator, Purdue University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07918196
- Sponsor's protocol ID
- STUDY2026-00000273
- Status last verified
- Nov 2026
- First submitted
- 13 Oct 2026
- Last updated
- 5 Nov 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be publicly shared. Deidentified data may be shared with study investigators and collaborators for analysis and publication.
Study at a glance
From the registry record, last updated by the sponsor on 5 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Postprandial Glycemic and GLP-1 Responses to Modified Full-sugar Drinks
- ClinicalTrials.gov ID
- NCT07918196
- Acronym / sponsor ID
- STUDY2026-00000273
- Conditions
- Postprandial Glucose, GLP-1 Concentration, Satiety
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 16 participants (estimated)
- Lead sponsor
- Purdue UniversityUniversity, hospital or other
- Study start
- 21 Oct 2026 (actual)
- Primary completion
- Dec 2026 (estimated)
- Study completion
- Dec 2026 (estimated)
- First posted
- 5 Nov 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This randomized, double-blind, crossover study will evaluate postprandial blood glucose and glucagon-like peptide-1 (GLP-1) responses to different sugar-containing beverages in healthy adults. The study will also evaluate whether the addition of epigallocatechin gallate (EGCG), a compound found in green tea, modifies glucose and GLP-1 responses. Participants will complete four study visits and consume a different study beverage at each visit. Blood samples will be collected to measure glucose, GLP-1, and insulin, and participants will complete questionnaires assessing satiety and sensory perception.
Detailed description
This study will investigate postprandial blood glucose and glucagon-like peptide-1 (GLP-1) responses to different sugar-containing beverages in healthy adults. The study will also examine whether the addition of epigallocatechin gallate (EGCG), a compound found in green tea, modifies postprandial glucose and GLP-1 responses. Additional outcomes include insulin, satiety, and sensory perception of the beverages.
The study will use a randomized, double-blind, crossover design in which each participant will complete four study visits and receive each of the four beverage conditions in a randomized order. The test beverages will contain sucrose or glucose plus fructose and will be provided with or without 200 mg of EGCG, according to the assigned treatment condition. Study visits will be separated by a washout period of at least one week.
Participants will consume a standardized evening meal before each study visit and will fast overnight for approximately 12 hours. At each study visit, an intravenous catheter will be placed for repeated blood collection. A fasting blood sample will be collected before consumption of the assigned beverage, followed by serial blood samples during the postprandial period. Blood samples will be analyzed for glucose, GLP-1, and insulin.
Participants will also complete questionnaires to assess satiety and sensory characteristics of the test beverages.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind (participant, investigator)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Sucrose beverage | Experimental | Dietary Supplement: Sucrose BeverageParticipants will consume a sugar-containing carbonated beverage formulated with sucrose. |
| Sucrose + EGCG beverage | Experimental | Dietary Supplement: Sucrose with EGCG BeverageParticipants will consume a sugar-containing carbonated beverage formulated with sucrose and 200 mg EGCG. |
| Glucose + Fructose beverage | Experimental | Dietary Supplement: Glucose + Fructose beverageParticipants will consume a sugar-containing carbonated beverage formulated with separate glucose and fructose. |
| Glucose + Fructose +EGCG beverage | Experimental | Dietary Supplement: Glucose-Fructose with EGCG BeverageParticipants will consume a sugar-containing carbonated beverage formulated with separate glucose and fructose and 200 mg EGCG. |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (6 listed)
- Adults aged 18 to 45 years at the time of enrollment (self-report)
- Body mass index (BMI) between 18.5 and 24.9 kg/m² (self-report in prescreening questionnaire and confirmed in screening with height and weight measurements)
- Fasting blood glucose ≤100 mg/dL (assessed in the screening visit by finger prick)
- HbA1c ≤ 5.7% (assessed in the screening visit by finger prick)
- Non-smokers (self-report)
Key exclusion criteria (9 listed)
- Diabetic or pre-diabetic or use of glucose-lowering medications.
- Pregnant or lactating individuals.
- Use of medications or supplements known to affect glucose metabolism or gastrointestinal function. Examples: corticosteroids, beta-blockers, insulin, metformin, statins, vitamin C, vitamin E.
- History of gastrointestinal disease or surgery affecting digestion or absorption, such as irritable bowel syndrome, Crohn's disease, celiac disease, or major GI surgery.
- Known allergy or intolerance to study beverage components, including caffeine or EGCG.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Sucrose BeverageCarbonated test beverage containing sucrose as the carbohydrate source. Participants will consume the beverage during one study visit. | Dietary supplement | Sucrose beverage |
| Glucose + Fructose beverageCarbonated test beverage containing separate glucose and fructose as the carbohydrate sources. Participants will consume the beverage during one study visit. | Dietary supplement | Glucose + Fructose beverage |
| Sucrose with EGCG BeverageCarbonated test beverage containing sucrose as the carbohydrate source plus EGCG. Participants will consume the beverage during one study visit. | Dietary supplement | Sucrose + EGCG beverage |
| Glucose-Fructose with EGCG BeverageCarbonated test beverage containing fructose and glucose as the carbohydrate source, plus EGCG. Participants will consume the beverage during one study visit. | Dietary supplement | Glucose + Fructose +EGCG beverage |
Primary outcome
Postprandial blood glucose
Time frame: Baseline (0 minutes) and 15, 30, 60, 90, 120, and 180 minutes after beverage consumption.
Changes in plasma glucose concentrations following consumption of each test beverage.
Postprandial GLP-1 response
Time frame: Baseline (0 minutes) and 15, 30, 60, 90, 120, and 180 minutes after beverage consumption.
Changes in plasma total glucagon-like peptide-1 (GLP-1) concentrations following consumption of each test beverage.
3 secondary outcomes
Postprandial insulin response
Time frame: Baseline (0 minutes) and 15, 30, 60, 90, 120, and 180 minutes after beverage consumption.
Satiety
Time frame: Baseline (0 minutes) and 15, 30, 45, 60, 90, 120, 150, and 180 minutes after beverage consumption.
Sensory perception of test beverages
Time frame: Immediately after beverage consumption during each study visit
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Nov 2026.
- Individual participant dataSharing planned: No. Individual participant data will not be publicly shared. Deidentified data may be shared with study investigators and collaborators for analysis and publication.
Related trials for Postprandial Glucose
Not yet recruitingPhase 2
Effects of Meal Macronutrients on Postprandial Lipids
Nephrotic Syndrome, Lipodystrophy
Not yet recruiting
SUVY VerSus SAccharose (SUVISA)
Healthy Volunteers, Erythritol
Recruiting
Sex Differences in Metabolism Following a High-fat Meal
Healthy Nutrition
RecruitingObservational study
Postprandial Glucose Handing in Contraceptive and IUD Users
Glucose Homeostasis
Not yet recruiting
A Crossover Study Evaluating the Postprandial Glycemic Response of Three Sweeteners in a Mixed Meal Setting
Postprandial Glucose, GI Tolerance
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Bruce Hamaker principal investigator
Purdue University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Sucrose Beverage, Glucose + Fructose beverage and Sucrose with EGCG Beverage in people with Postprandial Glucose and GLP-1 Concentration, run by Purdue University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 5 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Postprandial blood glucose (time frame: Baseline (0 minutes) and 15, 30, 60, 90, 120, and 180 minutes after beverage consumption.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Nov 2026.